JP2022506829A5 - - Google Patents
Info
- Publication number
- JP2022506829A5 JP2022506829A5 JP2021524438A JP2021524438A JP2022506829A5 JP 2022506829 A5 JP2022506829 A5 JP 2022506829A5 JP 2021524438 A JP2021524438 A JP 2021524438A JP 2021524438 A JP2021524438 A JP 2021524438A JP 2022506829 A5 JP2022506829 A5 JP 2022506829A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- breast cancer
- eribulin
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862758388P | 2018-11-09 | 2018-11-09 | |
| US62/758,388 | 2018-11-09 | ||
| PCT/US2019/061010 WO2020097625A1 (en) | 2018-11-09 | 2019-11-12 | Therapeutic regimens for treatment of cancer using eribulin and selective cdk4/6 inhibitor combinations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022506829A JP2022506829A (ja) | 2022-01-17 |
| JP2022506829A5 true JP2022506829A5 (enExample) | 2022-11-21 |
Family
ID=70612537
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021524438A Pending JP2022506829A (ja) | 2018-11-09 | 2019-11-12 | エリブリンと選択的ｃｄｋ４／６阻害剤との組合せを使用する癌の処置のための治療レジメン |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20210267986A1 (enExample) |
| EP (1) | EP3877422A4 (enExample) |
| JP (1) | JP2022506829A (enExample) |
| CN (1) | CN113271977A (enExample) |
| WO (1) | WO2020097625A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20190092478A (ko) | 2016-12-05 | 2019-08-07 | 쥐원 쎄라퓨틱스, 인크. | 화학요법 레지멘 동안의 면역 반응의 보존 |
| MX2019008158A (es) | 2017-01-06 | 2019-12-09 | G1 Therapeutics Inc | Terapia de combinacion para el tratamiento del cancer. |
| KR20230012547A (ko) | 2020-05-19 | 2023-01-26 | 쥐원 쎄라퓨틱스, 인크. | 의학적 장애의 치료를 위한 시클린-의존성 키나제 억제 화합물 |
| WO2022087018A1 (en) * | 2020-10-19 | 2022-04-28 | G1 Therapeutics, Inc. | Improved fluorouracil-based multi-agent chemotherapy for treatment of metastatic colorectal cancer |
| CN114748480B (zh) * | 2021-01-08 | 2023-10-20 | 轩竹生物科技股份有限公司 | 一种预防和/或治疗癌症的药物组合物 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX338327B (es) * | 2010-10-25 | 2016-04-12 | G1 Therapeutics Inc | Inhibidores de cdk. |
| RU2689977C2 (ru) * | 2012-12-04 | 2019-05-30 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Применение эрибулина для лечения рака молочной железы |
| ME03557B (me) * | 2013-03-15 | 2020-07-20 | G1 Therapeutics Inc | Privremena zaštiтa normalnih ćelija током hemoterapije |
| CA2940983A1 (en) * | 2014-03-03 | 2015-09-11 | Eisai R&D Management Co., Ltd. | Use of eribulin and mtor inhibitors as combination therapy for the treatment of cancer |
| WO2015161288A1 (en) * | 2014-04-17 | 2015-10-22 | G1 Therapeutics, Inc. | Tricyclic lactams for use as anti-neoplastic and anti-proliferative agents |
| US20170100367A1 (en) * | 2014-05-28 | 2017-04-13 | Eisai R&D Management Co., Ltd. | Use of eribulin in the treatment of cancer |
| EP3191098A4 (en) * | 2014-09-12 | 2018-04-25 | G1 Therapeutics, Inc. | Combinations and dosing regimes to treat rb-positive tumors |
| US20160166536A1 (en) * | 2014-12-12 | 2016-06-16 | Northwestern University | Combination therapy for the treatment of cancer |
| WO2016126889A1 (en) * | 2015-02-03 | 2016-08-11 | G1 Therapeutics, Inc. | Cdk4/6 inhibitor dosage formulations for the protection of hematopoietic stem and progenitor cells during chemotherapy |
| WO2018005533A1 (en) * | 2016-07-01 | 2018-01-04 | G1 Therapeutics, Inc. | Antiproliferative pyrimidine-based compounds |
| JP2019524748A (ja) * | 2016-07-20 | 2019-09-05 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | がんの治療におけるエリブリン及びヒストンデアセチラーゼ阻害剤の使用 |
| KR20190092478A (ko) * | 2016-12-05 | 2019-08-07 | 쥐원 쎄라퓨틱스, 인크. | 화학요법 레지멘 동안의 면역 반응의 보존 |
| MX2019008158A (es) * | 2017-01-06 | 2019-12-09 | G1 Therapeutics Inc | Terapia de combinacion para el tratamiento del cancer. |
| CN110891588A (zh) * | 2017-05-11 | 2020-03-17 | 艾瑞朗医疗公司 | 拟肽大环化合物及其用途 |
| US20200129473A1 (en) * | 2017-07-21 | 2020-04-30 | Eisai R&D Management Co., Ltd. | Use of eribulin and cyclin dependent kinase inhibitors in the treatment of cancer |
-
2019
- 2019-11-12 CN CN201980088426.8A patent/CN113271977A/zh active Pending
- 2019-11-12 WO PCT/US2019/061010 patent/WO2020097625A1/en not_active Ceased
- 2019-11-12 EP EP19881900.5A patent/EP3877422A4/en not_active Withdrawn
- 2019-11-12 JP JP2021524438A patent/JP2022506829A/ja active Pending
-
2021
- 2021-05-07 US US17/315,011 patent/US20210267986A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022506829A5 (enExample) | ||
| JP2022031403A5 (enExample) | ||
| ES2561495T3 (es) | Régimen de tratamiento que utiliza neratinib contra cáncer de mama | |
| TWI873485B (zh) | 用於治療癌症之方法及包含cdk2抑制劑及cdk4抑制劑之給藥方案 | |
| JP2012515184A (ja) | 大腸がんの治療方法 | |
| CA3146346A1 (en) | 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid for use in metastatic or advanced breast cancer patients | |
| BR112020010435A2 (pt) | uso de inibidor da parp no tratamento de câncer de ovário ou câncer de mama resistente à quimioterapia | |
| BR112020024062A2 (pt) | métodos para o tratamento de tumores de restos adrenais de testículo e de ovário | |
| JP2019529581A5 (enExample) | ||
| CN106573042A (zh) | 治疗多发性骨髓瘤的药物组合 | |
| JP2017526695A5 (enExample) | ||
| TW202120096A (zh) | 使用包含atp競爭性akt抑制劑、cdk4/6抑制劑及氟維司群之組合療法治療乳癌 | |
| JP2015517523A5 (enExample) | ||
| CN109069469A (zh) | 治疗癌症的方法 | |
| JP2019526632A5 (enExample) | ||
| US20250319084A1 (en) | Endocrine therapy and abemaciclib combination for the adjuvant treatment of node-positive, early stage, hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer | |
| ES2841981T3 (es) | Antihistamínico para su uso en el tratamiento del cáncer de mama | |
| JP2013531073A5 (enExample) | ||
| CN111184863A (zh) | 酪氨酸激酶抑制剂、cdk4/6抑制剂、serd联合在制备治疗肿瘤的药物中的用途 | |
| JP2021505669A5 (enExample) | ||
| JP5858989B2 (ja) | 組合せ | |
| CN119997942A (zh) | 用于治疗癌症的化合物 | |
| Chalasani | Optimizing quality of life in patients with hormone receptor-positive metastatic breast cancer: treatment options and considerations | |
| WO2019017497A1 (en) | USE OF CYCLIN-DEPENDENT KINASE ERIBULINE AND INHIBITORS IN THE TREATMENT OF CANCER | |
| JP2020521786A5 (enExample) |